Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | HRH2 | P25021 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL104699 | 1.00 | SIGMAR1 (0.51) | SIGMAR1CYP2C19MAPTSLC6A2SLC6A4 | |
| SCHEMBL104186 | 1.00 | SIGMAR1 (0.51) | SIGMAR1CYP2C19MAPTSLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL27966160 | 0.98 | SIGMAR1 (0.50) | SIGMAR1CYP2C19MAPTSLC6A2SLC6A4 | |
| Dimethylamine SCHEMBL8560100 | 0.95 | SIGMAR1 (0.47) | SIGMAR1CYP2C19MAPTSLC6A2SLC6A4 | |
| SCHEMBL15093677 | 0.91 | HRH3 (0.46) | SIGMAR1CYP2C19MAPTHRH2 | |
| Pyridine SCHEMBL28167226 | 0.90 | TP53 (0.44) | SIGMAR1CYP2C19MAPTSLC6A2SLC6A4 | |
| Trifluoroacetic Acid SCHEMBL2915951 | 0.88 | PDK1 (0.46) | SIGMAR1CYP2C19MAPTSLC6A2SLC6A4 | |
| SCHEMBL17460241 | 0.87 | HTR1A (0.42) | SIGMAR1SLC6A2SLC6A4SLC6A3HTR2C | |
| SCHEMBL19281788 | 0.87 | HTR1A (0.42) | SIGMAR1SLC6A2SLC6A4SLC6A3HTR2C | |
| Tert-Butyl Formate SCHEMBL27994114 | 0.85 | CYP2C19 (0.43) | SIGMAR1CYP2C19MAPTSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116496272-B | 7-Benzyl piperazinyl-9-allyl dehydropeganine derivative and preparation method and application thereof | 延安大学 | 2024-08-13 | — | — | CN | claimed |
| CN-116496272-A | 7-benzyl piperazinyl-9-allyl dehydropeganine derivative and preparation method and application thereof | 延安大学 | 2023-07-28 | — | — | CN | claimed |
| CN-104379578-B | Carbamate compounds and its preparation and application | 阿比德治疗公司 | 2017-06-09 | — | — | CN | claimed |
| US-20260132120-A1 | SMALL-MOLECULE MODULATORS OF THE ORPHAN NUCLEAR RECEPTOR TLX | BAYLOR COLLEGE OF MEDICINE (US) | 2026-05-14 | — | — | US | disclosed |
| US-12545657-B2 | Small-molecule modulators of the orphan nuclear receptor TLX | BAYLOR COLLEGE OF MEDICINE (US) | 2026-02-10 | — | — | US | disclosed |
| CN-116496272-B | 7-Benzyl piperazinyl-9-allyl dehydropeganine derivative and preparation method and application thereof | 延安大学 | 2024-08-13 | — | — | CN | disclosed |
| US-20240067625-A1 | SMALL-MOLECULE MODULATORS OF THE ORPHAN NUCLEAR RECEPTOR TLX | BAYLOR COLLEGE OF MEDICINE (US) | 2024-02-29 | — | — | US | disclosed |
| CN-116254059-B | Chemical mechanical polishing composition for edge polishing | 昂士特科技(深圳)有限公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-117377664-A | Small molecule modulators of orphan nuclear receptor TLX | 贝勒医学院 | 2024-01-09 | — | — | CN | disclosed |
| CN-117255689-A | NMN and derivatives for the treatment of depression and/or anxiety in patients suffering from one form of Parkinson's disease | 努瓦米德公司 | 2023-12-19 | — | — | CN | disclosed |
| CN-115926629-B | Chemical mechanical polishing composition with improved recycling properties | 昂士特科技(深圳)有限公司 | 2023-12-05 | — | — | CN | disclosed |
| WO-2002058695-A9 | (HALO-BENZO CARBONYL)HETEROCYCLO FUSED PHENYL P38 KINASE INHIBITING AGENTS | MERCK & CO INC (US) | 2003-09-12 | — | — | WO | disclosed |
| WO-2002058695-A1 | (HALO-BENZO CARBONYL)HETEROCYCLO FUSED PHENYL P38 KINASE INHIBITING AGENTS | MERCK & CO., INC. (US) | 2002-08-01 | — | — | WO | disclosed |
| CN-1067684-C | Imidazo [1,5-1] quinolines for treatment of anxiety and sleep disorders | PHAMACIA UPJOHN CO (US) | 2001-06-27 | — | — | CN | disclosed |
| US-6221868-B1 | Remedies/preventives for frequent urination/urinary incontinence and tropone derivatives | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2001-04-24 | — | — | US | disclosed |
| CN-1261347-A | Remedies/preventives for frequent urination/urinary incontinence and tropone derivatives | NIPPON KAYAKU KK (JP) | 2000-07-26 | — | — | CN | disclosed |
| EP-0995741-A1 | REMEDIES/PREVENTIVES FOR FREQUENT URINATION/URINARY INCONTINENCE AND TROPONE DERIVATIVES | Nippon Kayaku Kabushiki Kaisha (JP) | 2000-04-26 | — | — | EP | disclosed |
| CN-1135753-A | Imidazo [1, 5-a ] quinolines for the treatment of anxiety and sleep disorders | UPJOHN CO (US) | 1996-11-13 | — | — | CN | disclosed |
| US-4880806-A | BACTERICIDES | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1989-11-14 | — | — | US | disclosed |
| US-4874764-A | ANTIMICROBIALS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1989-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545657-B2 | Small-molecule modulators of the orphan nuclear receptor TLX | NR2E1, NR2C2, NR0B1 | SIGMAR1 235/4885CYP2C19 4649/4885MAPT 983/4885 |
| US-20240067625-A1 | SMALL-MOLECULE MODULATORS OF THE ORPHAN NUCLEAR RECEPTOR TLX | NR2E1, NR2E3, NR4A2 | SIGMAR1 812/4885CYP2C19 4706/4885MAPT 559/4885 |
| US-20260132120-A1 | SMALL-MOLECULE MODULATORS OF THE ORPHAN NUCLEAR RECEPTOR TLX | NR2E1, NR0B1, NR2C2 | SIGMAR1 226/4885CYP2C19 4661/4885MAPT 1004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.